

Asparlas[™] (calaspargase pegol-mknl) – New orphan drug approval

- On December 20, 2018, the FDA approved Servier Pharma's Asparlas (calaspargase pegol-mknl), • as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years.
- ALL is a form of leukemia that can progress quickly, and if not treated, can be fatal within a few • months. According to the American Cancer Society, there were about 5,960 new cases and 1,470 deaths from ALL in 2018.
 - The risk for developing ALL is highest in children younger than 5 years of age. The risk then declines slowly until the mid-20s, and begins to rise again slowly after age 50.
- Asparlas contains an asparagine specific enzyme and the pharmacological effect of Asparlas is . thought to be based on selective killing of leukemic cells due to depletion of plasma L-asparagine.
 - Oncaspar[®] (pegaspargase) is another asparagine specific enzyme approved for treatment of ALL.
- The efficacy of Asparlas for the treatment of ALL was based on a demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL. The pharmacokinetics of Asparlas were studied when used in combination with multiagent chemotherapy in 124 patients with B cell lineage ALL.
 - The results showed that 123 (99%, 95% CI: 96, 100) of the 124 patients maintained NSAA > 0.1 U/mL at weeks 6, 12, 18, 24 and 30,
- Asparlas is contraindicated in patients with a history of serious hypersensitivity reactions to • pegylated L-asparaginase, serious thrombosis during L-asparaginase therapy, serious pancreatitis related to previous L-asparaginase treatment, or serious hemorrhagic events during previous Lasparaginase therapy; and in patients with severe hepatic impairment.
- Warnings and precautions of Asparlas include hypersensitivity, pancreatitis, thrombosis, • hemorrhage, and hepatotoxicity.
- The most common grade > 3 adverse reactions (≥ 10%) with Asparlas use were elevated • transaminase, bilirubin increased, pancreatitis, and abnormal clotting studies.
- The recommended dose of Asparlas is 2,500 units/m² given intravenously no more frequently than • every 21 days.
- Servier Pharma's launch plans for Asparlas are pending. Asparlas will be available as a 3,750 units/5 mL (750 units/mL) single-dose vial for injection.



optumrx.com

Optum Rx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the Optum Rx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.